Driven by GLP-1 shortages and FDA compounding restrictions, a multi-billion-dollar gray market for injectable peptides ...
Novo Nordisk filed a lawsuit against Eli Lilly that alleges advertising falsely claims Wegovy is weaker than it is.
Medicare's new GLP-1 Bridge program offers weight-loss drugs for $50 a month, but the copay sidesteps Part D's cap and Extra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results